AI-assisted analysis based on the official CRS summary. Source version: Aug 13, 2025. Analysis updated: Sep 15, 2026.
01 — The Text
What.
- Expands existing federal grants to first responders to include rapid test strips that detect fentanyl, xylazine, and other synthetic opioids or emerging substances
- Requires the Department of Health and Human Services to publish guidance and standards for test strip manufacturers to support development, evaluation, and authorization
- Requires HHS to conduct a study and report to Congress on how test strip availability and usage affects overdose frequency and substance use disorder treatment participation
02 — The Stakes
So what?
- The bill establishes federal support for test strip distribution but does not specify funding amounts, timelines, or which entities will receive grants
- Effects on overdose rates and treatment participation are uncertain; the bill mandates only that HHS study and report these impacts, not that specific outcomes will occur
- The bill does not establish legal liability protections, clinical efficacy requirements, or regulatory approval pathways for test strips
03 — The Path
Now what?
- Ordered to be reported by committee with 48-0 vote on July 21, 2026
- Committee markup sessions held July 20-21, 2026
- Forwarded from Subcommittee on Health to full committee by voice vote on June 25, 2026
- No subsequent legislative action recorded as of the provided data
Legislative History
Actions.
- Jul 21, 2026 — Committee Consideration and Mark-up Session Held
- Jul 21, 2026 — Ordered to be Reported by the Yeas and Nays: 48 - 0.
- Jul 20, 2026 — Committee Consideration and Mark-up Session Held
- Jun 25, 2026 — Forwarded by Subcommittee to Full Committee by Voice Vote.
- Jun 25, 2026 — Subcommittee Consideration and Mark-up Session Held
- Feb 25, 2025 — Referred to the Subcommittee on Health.
- Feb 25, 2025 — Referred to the House Committee on Energy and Commerce.
- Feb 25, 2025 — Introduced in House